Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company specializing in Antibody Drug Conjugates (ADCs), announced that its shareholders approved all management proposals with a large majority (between 98.67% and 98.72%) at the ordinary virtual Annual General Meeting held today. The meeting, which saw an attendance of 80.55% of the current capital stock, formally approved the actions of the Management Board and Supervisory Board for the 2024/2025 financial year, appointed auditors for the 2025/2026 financial year, and approved the remuneration report for the Management Board.
Key resolutions included the election of Mr. Jack Yefei Ling as a new member of the Supervisory Board and an amendment to the Articles of Association to reduce the size of the Supervisory Board from seven to five members. The company noted that detailed voting results are available on the company's website at https://heidelberg-pharma.com/en/agm.
Heidelberg Pharma is pioneering the use of Amanitin, a toxin derived from the green death cap mushroom, in cancer therapies. Its proprietary ATAC technology leverages this compound to create innovative ADCs. The lead candidate, HDP-101 (INN: pamlectabart tismanitin), targets BCMA and is in clinical development for multiple myeloma, having received Orphan Drug Designation and Fast Track Designation from the FDA. A second candidate, HDP-102, is in clinical development for Non-Hodgkin Lymphoma. Additionally, HDP-103 for metastatic castration-resistant prostate cancer and HDP-104 targeting gastrointestinal tumors such as colorectal cancer have completed preclinical development and are available for partnering.
The outcomes of the Annual General Meeting reflect strong shareholder support for the company's strategic direction and governance. The election of Jack Yefei Ling brings new expertise to the Supervisory Board, which, with its reduced size, may enable more efficient decision-making. For investors and observers, these developments signal stability and alignment between management and shareholders, which is crucial as the company advances its pipeline of novel cancer therapies.
Heidelberg Pharma is based in Ladenburg, Germany, and listed on the Frankfurt Stock Exchange (ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA). More information about the company and its technology is available at www.heidelberg-pharma.com. ATAC® is a registered trademark of Heidelberg Pharma Research GmbH.
